• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

医疗保健公司对澳大利亚和新西兰医学协会的赞助:一项观察性研究。

Sponsorship of Australian and New Zealand medical societies by healthcare companies: an observational study.

作者信息

Lexchin Joel

机构信息

School of Health Policy and Management, York University, Toronto, M3J 1P3, Canada.

Faculty of Medicine, University of Toronto, Toronto, Canada.

出版信息

JRSM Open. 2022 Jul 7;13(7):20542704221111243. doi: 10.1177/20542704221111243. eCollection 2022 Jul.

DOI:10.1177/20542704221111243
PMID:35832836
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9272183/
Abstract

OBJECTIVES

To examine sponsorship of Australian and New Zealand medical societies by healthcare companies and whether societies have policies to deal with conflicts of interest.

DESIGN

Cross-sectional study conducted in March 2022.

SETTING

Australia and New Zealand.

PARTICIPANTS

Medical societies in both countries.

MAIN OUTCOME MEASURES

The percent of medical societies that list sponsorship from healthcare companies on either their home webpages or the webpages of their annual meetings and/or that issue prospectuses to potential sponsors. The percent of societies with sponsorship that also have policies about their interactions with their sponsors. Whether societies feature their sponsors' logos on their webpages and have hyperlinks to sponsors' webpages and what percent of societies' annual revenue comes from sponsorships.

RESULTS

Ninety-two medical societies were identified. Sixty-two had healthcare company sponsorship and 10 of the societies with sponsorship had policies to deal with interactions with their sponsors. Fifty-four societies displayed the logos of their sponsors on their home webpages and/or the webpages of their annual meetings. Only 6 societies provided enough information to calculate what percent of their revenue comes from sponsorships. For 5 of the 6 the percent was well below 50%.

CONCLUSIONS

The acceptance of sponsorships from healthcare companies by Australian and New Zealand societies is common and few societies have policies to deal with these relationships. In general, societies appear to get only a small percent of their annual revenue from sponsorships.

摘要

目的

研究医疗保健公司对澳大利亚和新西兰医学协会的赞助情况,以及协会是否有处理利益冲突的政策。

设计

2022年3月进行的横断面研究。

地点

澳大利亚和新西兰。

参与者

两国的医学协会。

主要观察指标

在其主页或年会网页上列出医疗保健公司赞助信息和/或向潜在赞助商发行招股说明书的医学协会百分比。有赞助的协会中也有关于与赞助商互动政策的协会百分比。协会在其网页上展示赞助商标志并设有指向赞助商网页的超链接的情况,以及协会年度收入中来自赞助的百分比。

结果

共识别出92个医学协会。62个协会有医疗保健公司的赞助,其中10个有赞助收入 的协会制定了处理与赞助商互动的政策。54个协会在其主页和/或年会网页上展示了赞助商的标志。只有6个协会提供了足够信息来计算其收入中来自赞助的百分比。这6个协会中有5个的这一百分比远低于50%。

结论

澳大利亚和新西兰的协会接受医疗保健公司赞助的情况很普遍,很少有协会制定处理这些关系的政策。总体而言,协会的年度收入中似乎只有一小部分来自赞助。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f834/9272183/350baa3c19f2/10.1177_20542704221111243-fig1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f834/9272183/350baa3c19f2/10.1177_20542704221111243-fig1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f834/9272183/350baa3c19f2/10.1177_20542704221111243-fig1.jpg

相似文献

1
Sponsorship of Australian and New Zealand medical societies by healthcare companies: an observational study.医疗保健公司对澳大利亚和新西兰医学协会的赞助:一项观察性研究。
JRSM Open. 2022 Jul 7;13(7):20542704221111243. doi: 10.1177/20542704221111243. eCollection 2022 Jul.
2
Conflict of interest between professional medical societies and industry: a cross-sectional study of Italian medical societies' websites.专业医学协会与行业之间的利益冲突:对意大利医学协会网站的横断面研究。
BMJ Open. 2016 Jun 1;6(6):e011124. doi: 10.1136/bmjopen-2016-011124.
3
National patient groups in Canada and their disclosure of relationships with pharmaceutical companies: a cross-sectional study.加拿大国家患者群体及其与制药公司关系的披露:一项横断面研究。
BMJ Open. 2022 Mar 9;12(3):e055287. doi: 10.1136/bmjopen-2021-055287.
4
Role modelling unhealthy behaviours: food and drink sponsorship of peak sporting organisations.角色模型不健康行为:高峰体育组织的食品和饮料赞助。
Health Promot J Austr. 2011 Apr;22(1):72-5. doi: 10.1071/he11072.
5
Pharmaceutical Industry Funding of Health Consumer Groups in Australia: A Cross-sectional Analysis.澳大利亚制药行业对健康消费者团体的资助:一项横断面分析。
Int J Health Serv. 2019 Apr;49(2):273-293. doi: 10.1177/0020731418823376. Epub 2019 Jan 15.
6
Sponsorship by food and beverage companies in soccer: an analysis of the 2019 Copa América.食品和饮料公司对足球赛事的赞助:2019年美洲杯分析
Rev Saude Publica. 2022 May 27;56:41. doi: 10.11606/s1518-8787.2022056003491. eCollection 2022.
7
Unhealthy sponsorship in sport: a case study of the AFL.运动中的不良赞助:澳式足球联盟案例研究。
Aust N Z J Public Health. 2018 Oct;42(5):474-479. doi: 10.1111/1753-6405.12820. Epub 2018 Aug 27.
8
Patterns of sports sponsorship by gambling, alcohol and food companies: an Internet survey.博彩、酒类和食品公司的体育赞助模式:一项互联网调查。
BMC Public Health. 2006 Apr 11;6:95. doi: 10.1186/1471-2458-6-95.
9
The impact of unhealthy food sponsorship vs. pro-health sponsorship models on young adults' food preferences: a randomised controlled trial.不健康食品赞助与促进健康的赞助模式对年轻成年人食物偏好的影响:一项随机对照试验。
BMC Public Health. 2018 Dec 20;18(1):1399. doi: 10.1186/s12889-018-6298-4.
10
Unhealthy and health promoting sponsorship of male and female professional sporting teams in Australia.澳大利亚男女职业运动队的不良和促进健康的赞助。
Health Promot J Austr. 2024 Oct;35(4):1352-1361. doi: 10.1002/hpja.824. Epub 2023 Nov 23.

引用本文的文献

1
Pharmaceutical industry payments to healthcare professional organisations in the United Kingdom: a seven-year cross-sectional analysis of the Disclosure UK database from 2015 to 2021.英国制药行业向医疗专业组织的付款:对2015年至2021年英国披露数据库的七年横断面分析。
J R Soc Med. 2025 Jan;118(1):16-25. doi: 10.1177/01410768241297441. Epub 2024 Nov 18.

本文引用的文献

1
Sponsorship of Canadian Professional Medical Societies by Drug, Medical Device and Medical Technology Companies: a Cross-sectional Study.药品、医疗器械和医疗技术公司对加拿大专业医学协会的赞助:一项横断面研究。
J Gen Intern Med. 2022 Dec;37(16):4280-4282. doi: 10.1007/s11606-022-07623-0. Epub 2022 Apr 27.
2
Pharmaceutical industry payments and assisted reproduction in Australia: a retrospective observational study.澳大利亚制药业的支付与辅助生殖:一项回顾性观察研究。
BMJ Open. 2021 Aug 31;11(9):e049710. doi: 10.1136/bmjopen-2021-049710.
3
Confirmatory Trial for Drug to Prevent Preterm Birth Finds No Benefit, So Why Is It Still Prescribed?
预防早产药物的验证性试验未发现益处,那为何仍在开这种药?
JAMA. 2020 Apr 7;323(13):1229-1232. doi: 10.1001/jama.2020.1486.
4
Pharmaceutical industry payments to leaders of professional medical associations in Australia: Focus on cardiovascular disease and diabetes.澳大利亚制药行业向专业医学协会领导人的支付情况:关注心血管疾病和糖尿病。
Aust J Gen Pract. 2020 Mar;49(3):151-154. doi: 10.31128/AJGP-08-19-5041.
5
Drivers of the opioid crisis: An appraisal of financial conflicts of interest in clinical practice guideline panels at the peak of opioid prescribing.阿片类药物危机的驱动因素:在阿片类药物处方高峰期评估临床实践指南小组中的财务利益冲突。
PLoS One. 2020 Jan 24;15(1):e0227045. doi: 10.1371/journal.pone.0227045. eCollection 2020.
6
Changes in the type and amount of spending disclosed by Australian pharmaceutical companies: an observational study.澳大利亚制药公司披露的支出类型和金额变化:一项观察性研究。
BMJ Open. 2019 Feb 19;9(2):e024928. doi: 10.1136/bmjopen-2018-024928.
7
Conflict of interest between professional medical societies and industry: a cross-sectional study of Italian medical societies' websites.专业医学协会与行业之间的利益冲突:对意大利医学协会网站的横断面研究。
BMJ Open. 2016 Jun 1;6(6):e011124. doi: 10.1136/bmjopen-2016-011124.
8
Industry working with physicians through professional medical associations.与医生合作的行业通过专业医学协会。
J Vasc Surg. 2011 Sep;54(3 Suppl):41S-6S. doi: 10.1016/j.jvs.2011.04.068.
9
Information from pharmaceutical companies and the quality, quantity, and cost of physicians' prescribing: a systematic review.来自制药公司的信息以及医生处方的质量、数量和成本:系统评价。
PLoS Med. 2010 Oct 19;7(10):e1000352. doi: 10.1371/journal.pmed.1000352.
10
Professional medical associations and their relationships with industry: a proposal for controlling conflict of interest.专业医学协会及其与行业的关系:关于控制利益冲突的提议。
JAMA. 2009 Apr 1;301(13):1367-72. doi: 10.1001/jama.2009.407.